Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 3 of 10, showing 5 Applications out of 50 total, starting on record 11, ending on 15

# Protocol No Study Title Investigator(s) & Site(s)

11.

ECCT/23/09/05   LCCC 2236 Study
    LCCC  2236: Phase I study of self-administered Artesunate pessaries (vaginal inserts) for treatment of cervical precancer in HIV positive and HIV-negative women in Kenya    
Principal Investigator(s)
1. Chemtai Mungo
2. Jackton Omoto
Site(s) in Kenya
FACES, Lumumba Sub-county Hospital
 
View

12.

ECCT/17/04/01   Odón Device for assisted vaginal delivery
    Feasibility, safety and preliminary efficacy study of a new device (Odón  Device) for assisted vaginal delivery   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
Kenyatta National Hospital
 
View

13.

ECCT/23/01/03   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Githanga Githanga Nyokabi
Site(s) in Kenya
1. Gertrude\'s Children Hospital (Nairobi City county)
2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county)
4. Kombewa CRC (Kisumu county)
 
View

14.

ECCT/12/11/02   Not provided
    A5297: An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of   Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and <350 cells/mm3   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

15.

ECCT/17/05/04   Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost
    A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
KEMRI WALTER REED KERICHO
 
View